CD32-dependent platelet activation by a drug-dependent antibody to glycoprotein IIb/IIIa antagonists

 

 Buy Article Permissions and Reprints

Summary

Thrombocytopenia is observed with a frequency of up to 2% in patients treated with glycoprotein (GP) IIb/IIIa antagonists. We recently provided evidence that thrombocytopenia is caused by antibody binding to drug-induced conformational changes in GP IIb/IIIa. Here, we report that a murine monoclonal antibody binds to GP IIb/IIIa in an antagonist-dependent manner and activates platelets. Platelet stimulation is associated with a disruption of the phospholipid asymmetry, resulting in the assembly of catalytic active intrinsic Xase and prothrombinase complexes. Further mechanistic studies revealed that this response is (I) mediated in cis, (II) not associated with the formation of pro-thrombotic microparticles, and (III) requires intact platelet signaling and (IV) is blocked by increases in cAMP. The prothrombotic response is not observed using F(ab’)₂ fragments and is blocked by incubation of platelets with neutralizing antibodies to the platelet FcγRIIa receptor (CD 32). Taken together, these observations suggest that GPIIb/IIIa antagonist-dependent antibody binding to the platelet fibrinogen receptor has the propensity to lead to CD32-mediated platelet activation and accelerated platelet clearance, leading to thrombocytopenia.

^*1 present address: Centocor Inc., Malvern, PA

^*2 present address: Incyte Genomics Inc., Newark, DE

• References

• 1 Cannon CP. The evolving story of oral platelet glycoprotein IIb/IIIa receptor inhibitors. Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drugs 2000; 2: 114-23.
  PubMedGoogle Scholar
• 2 Nurden AT, Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors: Basic and Clinical Aspects. Arterioscler Thromb Vasc Biol 1999; 19: 2835-40.
  CrossrefPubMedGoogle Scholar
• 3 The Prism Plus Investigators Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl J Med 1998; 338: 1488-97.
  CrossrefPubMedGoogle Scholar
• 4 The PURSUIT Trial Investigators Inhibition of platelet glycoprotein IIb/IIIa with eptifibratide in patients with acute coronary syndromes. New Engl J Med 1998; 339: 426-43.
  PubMedGoogle Scholar
• 5 The EPIC Investigators 1994 Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty. New Engl J Med 330: 956-61.
  PubMedGoogle Scholar
• 6 The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New Engl J Med. 1997 336. 1689-96.
  PubMedGoogle Scholar
• 7 The CAPTURE Investigators Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429-35.
  CrossrefPubMedGoogle Scholar
• 8 The EPISTENT Investigators Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess the safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockage. Lancet 1998; 352: 87-92.
  CrossrefPubMedGoogle Scholar
• 9 Billheimer JT, Dicker IB, Wynn R, Bradley JD, Cromley DA, Godonis HE, Grimminger LC, He B, Kieras CJ, Pedicord DL. et al Evidence that thrombocytopenia observed in humans treated with orally bioavailable glyco-protein IIb/IIIa antagonists is immune mediated. Blood 2002; 99: 3540-6.
  CrossrefPubMedGoogle Scholar
• 10 Seiffert D, Stern AM, Ebling W, Rossi RJ, Barrett YC, Wynn R, Hollis GF, He B, Kieras CJ, Pedicord DL. et al Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: Implications for the etiology of thrombocytopenia. Blood 2002; 101: 58-63.
  PubMedGoogle Scholar
• 11 Shulman NR, Reid DM. Platelet Immunology. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW. Philadelphia: Lippincott; 1994: 414-68.
  Google Scholar
• 12 Kelton JG. The serological investigation of patients with autoimmune thrombocytopenia. Thromb Haemost 1995; 74: 228-33.
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Chong BH. Drug-induced immune thrombocytopenia. Platelets 1991; 2: 173-81.
  CrossrefPubMedGoogle Scholar
• 14 Hackett T, Kelton JG, Powers P. Drug-induced platelet destruction. Semin Thromb Hemost 1982; 8: 116-37.
  Article in Thieme ConnectPubMedGoogle Scholar
• 15 Patton WN, Duffull SB. Idiosyncratic drug-induced haematological abnormalities. Pharmacoepidemiology 1994; 11: 445-62.
  PubMedGoogle Scholar
• 16 Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999; 36: 2-6.
  PubMedGoogle Scholar
• 17 Salzman EW, Hirsh J, Marder VJ. Clinical use of heparin. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW. Philadelphia: Lippincott: 1994: 1584-91.
  Google Scholar
• 18 Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards Consensus. Thromb Haemost 1998; 79: 1-7.
  Article in Thieme ConnectPubMedGoogle Scholar
• 19 Kunicki TJ. Platelet Immunology. In: Hemostasis and Thrombosis Philadelphia: Lippincott Williams & Wilkins; 2000: 461-77.
  Google Scholar
• 20 George JN. Platelet kinetics and pathophysiology of thrombocytopenia. In Hemostasis and Thrombosis Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Philadelphia: Lippincott Williams & Wilkins; 2000: 447-59.
  Google Scholar
• 21 Zolotarjova I N, Hollis GF, Wynn R. Unusually stable and long-lived ligand-induced conformations of integrins. J Biol Chem 2001; 276: 17063-8.
  CrossrefPubMedGoogle Scholar
• 22 Frelinger AL, Cohen I, Plow EF, Smith MA, Roberts J, Lam SC, Ginsberg MH. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem 1990; 265: 6346-52.
  PubMedGoogle Scholar
• 23 Frelinger AL, Du XP, Plow EF, Ginsberg MH. Monoclonal antibodies to ligand-occupied conformers of integrin alpha Ib beta 3 (glyco-protein IIb/IIIa) alter receptor affinity, specificity, and function. J Biol Chem 1991; 266: 17106-11.
  PubMedGoogle Scholar
• 24 Kouns WC, Kirchhofer D, Hadvary P, Eden-hofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidometic inhibitor. Blood 1992; 80: 2539-47.
  PubMedGoogle Scholar
• 25 Mondoro TH, Wall CD, White MM, Jennings LK. Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor. Blood 1996; 88: 3824-30.
  PubMedGoogle Scholar
• 26 Mazurov AV, Khaspekova SG, Byzova TV, Tikhomirov OY, Berndt MC, Steiner B, Kouns WC. Stimulation of platelet glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) functional activity by a monoclonal antibody to the N-terminal region of glycoprotein IIIa. FEBS Lett 1996; 391: 84-88.
  CrossrefPubMedGoogle Scholar
• 27 Hillman M, Zolotarjova NI, Patrick D, McCabe D, Shen K, Corman J, Billheimer JT, Seiffert D, Hollis GF. Large-scale purification of active platelet integrin glycoprotein IIb/IIIa. Protein Expr Purif 2002; 25: 494-502.
  CrossrefPubMedGoogle Scholar
• 28 Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res 1998; 90: 247-58.
  CrossrefPubMedGoogle Scholar
• 29 Dekkers DW, Comfurius P, Vuist WM, Bill-heimer JT, Dicker I, Weiss HJ, Zwaal RF, Bevers EM. Impaired calcium-induced tyrosine phosphorylation and defective lipid scrambling in erythrocytes from a patient with Scott’s syndrome: a study using an inhibitor for scramblase that mimics the defect in Scott syndrome. Blood 1998; 91: 2133-8.
  PubMedGoogle Scholar
• 30 Kouns WC, Wall CD, White MM, Fox CF, Jennings LK. A conformation-dependent epitope of human glycoprotein IIIa. J Biol Chem 1990; 265: 20594-601.
  PubMedGoogle Scholar
• 31 Gulino D, Ryckewaert JJ, Andrieuz A, Rabiet MJ, Marguerie G. Identification of a monoclonal antibody against platelet GP IIb that interacts with a calcium-binding site and induces aggregation. J Biol Chem 1990; 265: 9575-81.
  PubMedGoogle Scholar
• 32 Kouns WC, Jennings LK. Activation-independent exposure of the GP IIb-IIIa fibrinogen receptor. Thromb Res 1991; 63: 343-54.
  CrossrefPubMedGoogle Scholar
• 33 Modderman PW, Huisman HG, Mourik J, von dem Borne AEGK. A monoclonal antibody to the human platelet glycoprotein IIb/IIIa complex induces platelet activation. Thromb Haemost 1988; 60: 68-74.
  Article in Thieme ConnectPubMedGoogle Scholar
• 34 Hornby EJ, Brown S, Wilkinson JM, Mattock C, Authi KS. Activation of human platelets by exposure to a monoclonal antibody, PM6/248, to glycoprotein IIb/IIIa. Br J Haematol 1991; 79: 277-85.
  CrossrefPubMedGoogle Scholar
• 35 Bachelot C, Rendu F, Boucheix C, Hogg N, Levy-Toledano S. Activation of platelets induced by mAb P256 specific for glycoprotein IIb-IIIa. Eur J Biochem 1990; 190: 177-83.
  CrossrefPubMedGoogle Scholar
• 36 Bevers EM, Comfurius P, Reutelingsperger CPM, Zwaal RFA. Platelet procoagulant activity and its measurement. In: Platelets, a practical approach Watson SP, Authi KS. Oxford: IRL Press; 1996: 319-40.
  Google Scholar
• 37 Schick PK. Platelet and megakaryocyte lipids. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Philadelphia: Lippincott Williams & Wilkins: 2000: 522-532.
  Google Scholar
• 38 Tracy PB. Role of platelets and leukocytes in coagulation. In: Hemostasis and Thrombosis Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN. Phildadelphia: Lippincott Williams & Wilkins; 2000: 575-96.
  Google Scholar
• 39 Wilkinson JM. Monoclonal antibodies to platelet cell surface antigens and their use. In: Platelets, a practical approach Watson SP, Authi KS. Oxford: IRL Press; 1996: 155-72.
  Google Scholar